Home Overview Press Room Blog Publications For Students about us
Search

About the States' Policies & Human Biotechnology


Individual states are filling the regulatory void created by the federal government’s failure to provide comprehensive legislation governing human biotechnologies. This is creating an often inconsistent policy patchwork.

California

State action is evident in a number of areas, including embryonic stem cell, cloning, egg retrieval, and assisted reproduction. More than a dozen states have laws banning reproductive cloning, about half of which also prohibit cloning for stem cell research. Dozens of similar bills are introduced in other states each year.

In response to President Bush’s restrictions on the federal funding of human embryonic stem cell research, several states initiated their own funded research programs. California led the way in 2004 with Proposition 71, which set aside $3 billion of public funds for stem cell research over ten years.



Slippery Slopes and Biological Curve Balls: Updates on 3-person IVFby Leah LowthorpBiopolitical TimesDecember 13th, 2016There have been several recent setbacks and troubling developments in 3-person IVF technology and applications.
NY senator from LI introduces ‘familial DNA’ legislationby Chau LamNewsdayDecember 9th, 2016Critics of familial DNA searches point to high rates of false positives, invasion of privacy, and racial disparities.
Amid Lawsuit, San Diego Stem Cell Company Pushes Back On Proposed Regulationsby David WagnerKPBSDecember 5th, 2016Patients currently suing the company say they paid thousands of dollars for treatments that didn't work.
How Will Trump Use Science to Further His Political Agenda?by Sarah ZhangThe AtlanticDecember 1st, 2016We have a president-elect who appears to believe in his genetic superiority, with a chief strategist who has been reported to believe the same.
UK doctors to seek permission to create baby with DNA from three people by Ian SampleThe GuardianNovember 30th, 2016A scientific review concluded that the procedure should be approved for "cautious clinical use" when children are at risk of inheriting specific genetic diseases.
What’s behind those billion-dollar biotech deals? Often, a whole lot of hypeby Damian GardeSTATNovember 28th, 2016Huge deals are measured in "biobucks" — akin to lottery tickets that pay out if and when an experimental drug hits various milestones along the path to commercialization.
Abortion-By-Mail Study Outrages Opponentsby Phil GalewitzKQED California HealthlineNovember 16th, 2016A pilot study of telemedicine-based medical abortion demonstrates a welcome new option for women. Opponents of abortion find the concept deeply disturbing.
Where Traditional DNA Testing Fails, Algorithms Take Overby Lauren KirchnerProPublicaNovember 4th, 2016Various "probabilistic genotyping" programs undermine due process as defense attorneys, judges, and jurors can't access their proprietary inner workings.
The controversial DNA search that helped nab the 'Grim Sleeper' is winning over skepticsby Marisa GerberLos Angeles TimesOctober 25th, 2016Use of familial DNA to solve crimes is growing in popularity, raising concerns of 4th Amendment unreasonable search and seizure violations.
President signs Senate bill that protects eugenics victimsby Richard CraverWinston-Salem JournalOctober 7th, 2016State restitution payments will not decrease or eliminate federal benefits for people who were forcibly sterilized.
Displaying 1-10 of 494  
Next >> 
Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760